Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gurmeet Singh

Neurology St Clairsville, OH Medical Doctor

NPI 1518917152 CMS profile 250768

106 Plaza West, St Clairsville, OH 43950

Open in the dashboard

General payments

$2,801

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gurmeet Singh of St Clairsville, OH is reported in the CMS Open Payments database as having received $2,801 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $698 30
2024 General $545 31
2023 General $584 32
2022 General $165 11
2021 General $329 21
2020 General $201 12
2019 General $281 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gurmeet Singh
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gurmeet Singh were reported at $698. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gurmeet Singh Neurology median Middle half National median
2019 $281 $474 $118–$2,177 $163
2020 $201 $367 $82–$2,309 $114
2021 $329 $438 $104–$2,547 $132
2022 $165 $442 $103–$2,388 $149
2023 $584 $464 $119–$2,312 $160
2024 $545 $468 $119–$2,323 $164
2025 $698 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SK Life Science, Inc. $378 24 payments
  2. Harmony Biosciences LLC $366 20 payments
  3. Pfizer Inc. $354 21 payments
  4. Neurocrine Biosciences, Inc. $222 10 payments
  5. AbbVie, Inc. $188 10 payments
  6. Amgen Inc. $146 3 payments
  7. Biogen, Inc. $122 8 payments
  8. Amneal Pharmaceuticals LLC $121 8 payments
  9. Kyowa Kirin, Inc. $115 7 payments
  10. Allergan Inc. $93 5 payments
  11. Other $697 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,627 153 payments
  2. Education $161 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14 1 payment
Products named General payments · program years 2019–2025
  1. NURTEC ODT Pain $343 20 payments
  2. ZAVZPRET $223 13 payments
  3. INGREZZA $222 10 payments
  4. WAKIX Sleep Medicine $184 9 payments
  5. UBRELVY $159 9 payments
  6. NURTEC ODT Primary Care $127 8 payments
  7. NOURIANZ $115 7 payments
  8. UPLIZNA $112 1 payment
  9. ADUHELM $110 7 payments
  10. Wakix Neurological Disorders $109 7 payments
  11. Other $1,109 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

5,198

Median for Neurology: 833

Drug cost

$781,556

Median for Neurology: $202,670

Branded share of claims

22.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 24 $141,871
Rytary Carbidopa/Levodopa Brand 63 $79,620
Xcopri Cenobamate Brand 41 $57,891
Rexulti Brexpiprazole Brand 30 $47,384
Briviact Brivaracetam Brand 33 $46,968
Aimovig Autoinjector Erenumab-Aooe Brand 39 $44,725
Lacosamide Generic 161 $39,006
Nurtec Odt Rimegepant Sulfate Brand 30 $36,784
Emgality Pen Galcanezumab-Gnlm Brand 18 $24,106
Neupro Rotigotine Brand 13 $23,655

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$96,397

Medicare's payments for the services billed

Medicare patients

531

Average age 71

Services billed

1,218

280 women, 251 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 36%
Depression 35%
Ischemic heart disease 31%
Chronic kidney disease 23%
COPD 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $90
$90 30 —
WAKIX
  • Harmony Biosciences LLC $73
$73 — —
ZAVZPRET
  • PFIZER INC. $64
$64 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $46
$46 — —
UBRELVY
  • AbbVie, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record